March 9 (Reuters) - The U.S. health regulator issued a draft guidance on Monday to help drugmakers develop cheaper versions ...

The FDA has proposed new rules to speed up the development of biosimilar drugs, aiming to reduce the costs of biologic ...

LOS ANGELES, CA / ACCESS Newswire / March 10, 2026 / Today Technomark Life Sciences ( and MAX BioPharma ( announced their collaboration in the development of MAX BioPharma’s oxysterol drug candidate, ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

The collaboration brings together Scipher Medicine’s expertise in precision medicine and molecular patient stratification with Senelix’s therapeutic development capabilities to accelerate the ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

In a recently published review, a research team led by MedUni Vienna has highlighted a promising new approach to drug ...

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...

Discover why biomarkers are critical in modern drug discovery and clinical trials, enabling better target validation.

Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...

Xenon Pharmaceuticals said its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo.